Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay
Executive Summary
Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested
You may also be interested in...
Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns
Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data
Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns
Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data
Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec
Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month